SynthesisBMC pregnancy and childbirth2025
A multidisciplinary management model for severe gestational hypertriglyceridemia: using plasmapheresis to prevent pancreatitis in pregnancy.
Synthesis in BMC pregnancy and childbirth, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Hypertriglyceridaemia-Associated Acute Pancreatitis: Risk Stratification, Drivers, and Prevention of Recurrence.Diseases (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Severe gestational hypertriglyceridemia can lead to life-threatening pancreatitis with high maternal and fetal mortality, yet there are no established guidelines for managing these patients. We report two cases of severe gestational hypertriglyceridemia managed through a multidisciplinary approach. With the collaboration of obstetricians, endocrinologists, and nephrologists, we utilized a novel plasmapheresis circuit-combining centrifugation and filtration plasmapheresis (CFPP)-and performed regular sessions via peripheral venous access without the use of plasma or albumin. This treatment effectively lowered triglycerides in an attempt to prevent gestational pancreatitis, with no major maternal or fetal complications. We also conducted a systematic review of published reports on regular apheresis for severe gestational hypertriglyceridemia, identifying twenty-one additional cases. In these cases, treatment was generally administered twice weekly or every other week, with therapeutic plasmapheresis being the most frequently employed modality. The mean triglyceride reduction rate was 45.1%, and CFPP achieved the highest reduction rate (68.3% ± 7.2%). No maternal deaths were reported. Despite regular apheresis, four out of 23 patients (17.4%) experienced acute pancreatitis. The average triglyceride level at the onset of pancreatitis was 45.20 ± 4.65 mmol/L. Case reports support the use of regular apheresis for severe gestational hypertriglyceridemia. Multidisciplinary collaboration is essential for the care of these patients. More prospective and interventional studies are needed to guide clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.